Boundless dips during first day of trading

2024-03-28

IPO寡核苷酸

After a two-year slump, biotech IPOs came in hot to kick off 2024 with rapid fire and high figure raises. However, Boundless Bio’s lacklustre performance on its first day of trading may signal cooling enthusiasm.

After raising $100 million late Wednesday through the sale of 6.25 million shares at $16 each – the midpoint of its proposed offering – the cancer drug developer fell about 11% on Thursday to close at $14.25. The slip in share price values Boundless Bio at about $317 million.

Earlier-stage companies including metabolic-disease focused Fractyl Health and genetic medicines firm Metagenomi have also struggled to post positive trading gains following their public debuts in February. The former has fallen 51% from its IPO price, and the latter is down 30%.

Boundless has Phase I/II trials underway for two cancer programmes. The first is evaluating BBI-335, an oral checkpoint kinase 1 inhibitor checkpoint kinase 1 inhibitor, in patients with oncogene-amplified cancers; the the second is assessing BBI-825, which targets the ribonucleotide reductase enzyme in patients with resistance gene amplifications.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构